Руководитель лаборатории\НИЛ Биомаркер - Казанский (Приволжский) федеральный университет
Руководитель лаборатории НИЛ "Биомаркер"

Киямова Рамзия Галлямовна 

д.б.н., профессор, зав.кафедрой биохимии, биотехнологии и  фармакологии

(h-index-11) 

e-mail: kiyamova@mail.ru  

Профессор Киямова Рамзия Галлямовна является признанным специалистом в области молекулярных маркеров злокачественных новообразований. С помощью технологии SEREX (serological analysis of cDNA expression libraries) ею  выявлено более 100 опухоль-ассоциированных антигенов, многие из которых являются маркерам рака (2000-2012 годы)[1,2,3,4,5,6,7,8]. В 2005 году ей удалось с помощью модифицированного метода  SEREX выявить молекулярную природу антигена МХ35 как фосфатный транспортер NaPi2b, идентифицировать потенциальный опухоль-специфический эпитоп и предложить гипотетическую модель транспортера, что привело к публикации ряда статей и международного патента совместного c Memorial  Sloan Kettering Cancer Center (Нью-Йорк, США) (2005-2010 годы) [9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]. 


  1. Panel of SEREX-defined antigens for breast cancer autoantibodies profile detection. Kostianets O, Shyyan M, Antoniuk SV, Filonenko V, Kiyamova R. Biomarkers. 2017 Mar;22(2):149-156. doi: 10.1080/1354750X.2016.1252952. Epub 2016 Nov 9.PMID: 27775439
  2. Skripova V. CRISPR/Cas9 Technique for Identification of Genes Regulating Oxaliplatin Resistance of Pancreatic Cancer Cell Line/Skripova, V., Serebriiskii, I., Abramova, Z. Astsaturov I,  Kiyamova R.//BioNanoSci. - 2016. doi:10.1007/s12668-016-0272-3
  3. Autoantibody Response to ZRF1 and KRR1 SEREX Antigens in Patients with Breast Tumors of Different Histological Types and Grades. Dyachenko L, Havrysh K, Lytovchenko A, Dosenko I, Antoniuk S, Filonenko V, Kiyamova R. Dis Markers. 2016;2016:5128720. Epub 2016 Oct 25.PMID: 27847402
  4. Application of serex-analysis for identification of human colon cancer antigens. Garifulin OM, Kykot VO, Gridina NY, Kiyamova RG, Gout IT, Filonenko VV. Exp Oncol. 2015 Sep;37(3):173-80. PMID: 26422100
  5. Immunohistochemical analysis of medullary breast carcinoma autoantigens in different histological types of breast carcinomas. Kostianets O, Antoniuk S, Filonenko V, Kiyamova R. Diagn Pathol. 2012 Nov 26;7:161. doi: 10.1186/1746-1596-7-161. PMID: 23181716 Free PMC Article
  6. Serological analysis of SEREX-defined medullary breast carcinoma-associated antigens. Kostianets O, Shyian M, Sergiy D, Antoniuk S, Gout I, Filonenko V, Kiyamova R. Cancer Invest. 2012 Aug;30(7):519-27. doi: 10.3109/07357907.2012.697231. Epub 2012 Jun 19. PMID: 22712734
  7. Preliminary study of thyroid and colon cancers-associated antigens and their cognate autoantibodies as potential cancer biomarkers. Kiyamova R, Garifulin O, Gryshkova V, Kostianets O, Shyian M, Gout I, Filonenko V. Biomarkers. 2012 Jun;17(4):362-71. doi: 10.3109/1354750X.2012.677476. Epub 2012 May 22. PMID: 22612312
  8. Identification of Tumor-Associated Antigens from Medullary Breast Carcinoma by a Modified SEREX Approach / R. Kiyamova, O. Kostianets, S. Malyuchik, V. Filonenko, V. Usenko, V. Gurtovyy, Yu. Khozayenko, S. Antonuk, L. Old, I. Gout // Molecular Biotechnology. – 2010. - Vol. 46, № 2. – P. 105-112.
  9.  Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas / B.Yin, R. Kiyamova, R. Chua, O. Caballero,  I. Gout, V. Gryshkova, N. Bhaskaran, S. Souchelnytskyi, U. Hellman, V. Filonenko, A. Jungbluth, K. Odunsi, K. Lloyd, L. Old, G. Ritter // Cancer Immunity. - 2008. - [serial online]; 8:3 - Vol. 8, p. 3.
  10. Development of monoclonal antibodies specific for the human sodium-dependent phosphate cotransporter NaPi2b / R. Kiyamova, V. Gryshkova, G. Ovcharenko, D. Lituyev, S. Malyuchik, V. Usenko, Y. Khozhayenko, V. Gurtovyy, B. Yin, G. Ritter, L. Old, V. Filonenko, I. Gout // Hybridoma. – 2008. – Vol. 27, № 4.- P. 277-284.
  11. Generation of monoclonal antibodies against tumor-associated antigen MX35/sodium-dependent phosphate transporter NaPi2b.Gryshkova V, Lituiev D, Savinska L, Ovcharenko G, Gout I, Filonenko V, Kiyamova R. Hybridoma (Larchmt). 2011 Feb;30(1):37-42. PMID:21466284
  12. The study of phosphate transporter NaPi2b expression in different histological types of epithelial ovarian cancer / V. Gryshkova, I. Goncharuk, V. Gurtovyy, Yu. Khozhayenko, S. Nespryadko, L. Vorobjova, V. Usenko, I. Gout, V. Filonenko, R. Kiyamova // Experimental oncology. – 2009. – Vol. 31, № 1. – P. 37-42.
  13. Creation of cellular models for the analysis of sodium-dependent phosphate transporter NaPi2b, a potential marker for ovarian cancer / V. S. Gryshkova, D. S. Lituyev, V.V. Filonenko, R. G. Kiyamova  // Біополімери і клітина. – 2009. – Т. 25, № 2. – С. 95-100.
  14. Patent WO 2009/097128 A1, PCT/US2009/000576 Membrane transporter NaPi2b (SLC34A2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy / G. Ritter, B. Yin, A. Murray, G. Mark, L. Old, K. Lloyd, S. Souchelnytsiy, I. Gout, V. Filonenko, R. Kiyamova // International application date 29.01.2009, International publication date 06.08.2009.
  15. Lituyev D. Mutations in the gene of human type IIb sodium-phosphate cotransporter SLC34A2 / D. Lituyev, R. Kiyamova // Biopolymers and Cell. – 2010. – Vol.26, № 1. – P. 13-22.
  16. Immunohistochemical analysis of NaPi2b protein (MX35 antigen) expression and subcellular localization in human normal and cancer tissues / R. Kiyamova, M. Shyian, V.V. Lyzogubov, V.S. Usenko, T. Gout, V. Filonenko // Experimental Oncology. – 2011.- Vol. 33, №3. – P.157-161.
  17. Quantitative analysis of SLC34A2 expression in different types of ovarian tumors / M. Shyian, V. Gryshkova, O. Kostianets, V. Gorshkov, Yu. Gogolev, I. Goncharuk, S. Nespryadko, L. Vorobjova, V. Filonenko, R. Kiyamova // Experimental Oncology. – 2011. - Vol. 33, № 2. – P. 94-98.
  18. Effect of Anti-NaPi2b Monoclonal Antibody on Phosphate Transport in Renal Cancer Cell Line SK-RC-18 / R.G. Kiyamova, G.A. Savchenko, V. S. Gryshkova, G. V. Ovcharenko, Y. A Boychuk, O. O. Krishtal, V. V. Filonenko // International journal of physiology and pathophysiology. – 2011. - Vol. 2, № 3. –P. 279-289.